Table 1. Details of the included studies.
Study | Location | Reference standard | Index test | Specimen | Sample size | Study design | Patient population |
---|---|---|---|---|---|---|---|
Poovorawari et al 1994 [23] | Thailand | ELISA 2nd, RIBA | Spot | Serum | 192 | Case-control | Hospital samples |
Mvere et al 1996 [24] | Zimbabwe | EIA 2nd, INNO-LIA HCV Ab III | Spot | Serum | 206 | Cross-sectional | Blood bank |
Montebugnoli et al 1999 [25] | Italy | ELISA (Ortho HCV 3.0), RIBA | Rapid | Whole blood | 100 | Case-control | Hospital samples |
Kaur et al 2000 [26] | India | EIA 3rd | BiDot | Serum | 2754 | Cross-sectional | Hospital samples |
Buti et al 2000 [27] | Spain | Immunometric technique, RIBA | Multiplo | Serum | 188 | Case-control | Hospital samples |
Yuen et al 2001 [28] | China | EIA, PCR | SM-HCV | Serum | 290 | Case-control | Hospital samples |
WHO 2001 [29] | Switzerland | ELISA, RIBA, PCR | α | Serum | 257 | Case-control | WHO panel |
WHO 2001 [30] | Switzerland | ELISA, RIBA, PCR | TriDot 4th, Genedia | Serum | 257 | Case-control | WHO panel |
WHO 2002 [31] | Switzerland | ELISA, RIBA, PCR | SDBioline | Serum | 257 | Case-control | Asia, Africa, Latin America & Europe |
Hui et al 2002 [32] | Hong Kong | EIA | SM-HCV | Whole blood | 197 | Case-control | Hepatology clinic |
Daniel et al 2005 [33] | India | EIA, RIBA, PCR | TriDot | Serum | 2590 | Cross-sectional | Outpatient /hepatology |
Scheiblauer et al 2006 [12] | USA | EIA, PCR | β | Serum | 381 | Case-control | ICBS panel |
Njouom et al 2006 [34] | Cameroon | EIA 3rd, PCR | ImmunocombHexagon | Plasma | 329 | Case-control | NK |
Torane et al 2006 [35] | India | ELISA | Spot | Whole blood | 60 | Case-control | Blood banks |
Nyirenda et al 2008 [36] | Malawi | ELISA, CLIA, Lineimmunoassay | Spot | Serum | 202 | Cross-sectional | Outpatient clinics |
Ivantes et al 2010 [37] | Brazil | CLIA | Bioeasy | Whole blood | 71 | Cross-sectional | General population |
Lee et al 2010 [38] | USA | EIA, RIBA | OraQuick | £ | 572 | Cross-sectional | Low-risk persons |
Lee et al 2011 [39] | USA | EIA, RIBA, PCR | OraQuick | £ | 2176 | Case-control | Medical clinics |
Smith et al 2011 [40] | USA | CLIA, RIBA | ¥ | Serum | 1081 | Cross-sectional | Injection drug users |
Smith et al 2011 [41] | USA | MEIA/EIA/CLIA, RIBA | ¥ | Whole blood, Oral fluid | μ | Cross-sectional | Injection drug users |
Drobnik et al 2011 [42] | USA | EIA, RIBA | OraQuick | Oral fluid | 484 | Cross-sectional | High-risk groups |
Cha et al 2012 [43] | Korea | EIA | OraQuick | Oral fluid Serum | 437 | Case-control | Hospital samples |
Maity et al 2012 [44] | India | ELISA | TriDot | Serum | 300 | Case-control | NK |
Jewett et al 2012 [45] | USA | ELISA, RIBA, PCR | Chembio, Multiplo | Blood | 406 | Case-control | Injection drug users |
Kant et al 2012 [46] | Germany | Architect HCV | Onsite | Serum | 185 | Case-control | Hospital samples |
Kim et al 2013 [47] | Korea | ADVIA Centaur RIBA | SDBioline Genedia | Serum | 100 | Case control | Hospital samples |
Al-Tahish et al 2013 [48] | Egypt | ELISA 3rd, HCV RNA | One-step TriDot 4th Immunocomb | Serum | 100 | Case-control | Blood donors |
da Rosa et al 2013 [49] | Brazil | Architect HCV test, PCR | Bioeasy | Serum | 307 | Case-control | Hepatology clinic |
O'Connell et al 2013 [50] | USA | ELISA 3rd | € | Plasma | 674 | Case-control | Blood banks |
Tagny et al 2014 [51] | Cameron | ELISA | Hexagon | Plasma | 1998 | Cross-sectional | Blood banks |
NK = not known. α = Advanced, TriDot, Serodia, Spot, SeroCard. β = Acon, HepaScan, TriDot, Genedia, i+Lab, Dipstick, Assure, SPAN, ImmunoRAPIDO. ¥ = Chembio, Multiplo, OraQuick. € = OraQuick, Instant, Axiom, FirstVue. μ = 197, 282, 389, 285, 432, 265, 266. £ = Oral fluid, whole blood, finger stick, plasma, serum.